Results 21 to 30 of about 14,372 (211)

Reduction of the HIV protease inhibitor-induced ER stress and inflammatory response by raltegravir in macrophages. [PDF]

PLoS ONE, 2014
HIV protease inhibitor (PI), the core component of highly active antiretroviral treatment (HAART) for HIV infection, has been implicated in HAART-associated cardiovascular complications.
Xiaoxuan Zhang, Risheng Cao, Runping Liu, Renping Zhao, Yi Huang, Emily C Gurley, Phillip B Hylemon, William M Pandak, Guangji Wang, Luyong Zhang, Xiaokun Li, Huiping Zhou   +11 more
doaj   +1 more source

Comparison of illumina and 454 deep sequencing in participants failing raltegravir-based antiretroviral therapy. [PDF]

PLoS ONE, 2014
The impact of raltegravir-resistant HIV-1 minority variants (MVs) on raltegravir treatment failure is unknown. Illumina sequencing offers greater throughput than 454, but sequence analysis tools for viral sequencing are needed.
Jonathan Z Li, Brad Chapman, Patrick Charlebois, Oliver Hofmann, Brian Weiner, Alyssa J Porter, Reshmi Samuel, Saran Vardhanabhuti, Lu Zheng, Joseph Eron, Babafemi Taiwo, Michael C Zody, Matthew R Henn, Daniel R Kuritzkes, Winston Hide, ACTG A5262 Study Team, Cara C Wilson, Baiba I Berzins, Edward P Acosta, Barbara Bastow, Peter S Kim, Sarah W Read, Jennifer Janik, Debra S Meres, Michael M Lederman, Lori Mong-Kryspin, Karl E Shaw, Louis G Zimmerman, Randi Leavitt, Guy De La Rosa, Amy Jennings   +30 more
doaj   +1 more source

Real-World Characterization of the Portuguese Population Living with HIV who Initiated Raltegravir Based-Regimens: The REALITY Study

Acta Médica Portuguesa, 2022
Introduction: Although raltegravir has been available since 2007, data are lacking on the Portuguese population living with HIV who initiated this antiretroviral therapy.
Rosário Serrão, Kamal Mansinho, Fernando Maltez, Nuno Marques, Alexandre Carvalho, Rosário Pazos, Alexandra Zagalo, Josefina Mendez, Isabel Neves, Joaquim Oliveira, Patrícia Pacheco, Ricardo Correia de Abreu, Ana Cláudia Miranda, Paula Camacho, Laura Paixão, Joana Almeida   +15 more
doaj   +1 more source

Raltegravir, Indinavir, Tipranavir, Dolutegravir, and Etravirine against main protease and RNA-dependent RNA polymerase of SARS-CoV-2: A molecular docking and drug repurposing approach

Journal of Infection and Public Health, 2020
Background Outbreak of COVID-19 has been recognized as a global health concern since it causes high rates of morbidity and mortality. No specific antiviral drugs are available for the treatment of COVID-19 till date.
Purushothaman Indu, M. R. Ramesh Kumar, N. Arunagirinathan, N. Al-Dhabi, M. Valan Arasu, S. Ignacimuthu   +5 more
semanticscholar   +1 more source

Pharmacokinetic/pharmacodynamic investigation of raltegravir with or without lamivudine in the context of HIV-1 pre-exposure prophylaxis (PrEP)

Journal of Antimicrobial Chemotherapy, 2021
Background To characterize their potential use in pre-exposure prophylaxis (PrEP) we compared the pharmacokinetics of raltegravir and lamivudine in genital tissue against ex vivo tissue infection with HIV-1.
C. Herrera, J. Lwanga, Ming J. Lee, S. Mantori, A. Amara, L. Else, S. D. Penchala, D. Egan, E. Challenger, L. Dickinson, M. Boffito, R. Shattock, S. Khoo, J. Fox   +13 more
semanticscholar   +1 more source

Eficacia y seguridad en condiciones clínicas reales del raltegravir en un hospital de referencia del seguro social peruano

Enfermería Global, 2021
Introducción: El Rategravir pertenece a los inhibidores de integrasas, quedando demostrado y aprobado por diversos ensayos clínicos como un potente antirretroviral seguro y eficaz para el tratamiento de pacientes infectados con el virus de ...
Elias Contreras-Calero, Marcos Saavedra-Velasco, Fernando Mendo-Urbina , Carlos Muñoz-Medina, J. Antonio Grandez-Urbina, Rafael Pichardo-Rodriguez   +5 more
doaj   +1 more source

Longitudinal changes in plasma biomarkers of immune activation, neuronal inflammation and injury in persons with HIV initiating ART. [PDF]

HIV Med
Abstract Background Data on changes in biomarkers of brain health, and their associations with cognitive function in adults commencing either dual‐ or triple‐antiretroviral therapy (ART) are sparse. Methods Plasma biomarkers (neurofilament light [NfL], glial fibrillary acidic protein [GFAP], sCD14, CXCL10, neopterin and IL‐6) were measured at baseline ...
Henderson M, Dutey-Magni P, Herrera C, Stöhr W, Arenas-Pinto A, Swann O, Heslegrave A, Zetterberg H, Tregoning J, Fidler S, Raffi F, Calcagno A, Babiker A, Winston A.   +13 more
europepmc   +2 more sources

Raltegravir Is a Substrate for SLC22A6: a Putative Mechanism for the Interaction between Raltegravir and Tenofovir [PDF]

, 2011
The identification of transporters of the HIV integrase inhibitor raltegravir could be a factor in an understanding of the pharmacokinetic-pharmacodynamic relationship and reported drug interactions of raltegravir.
Back, David, David J. Back, Kwan, Wai San, Darren M. Moss, Darren L. Smith, Smith, Darren, Marco Siccardi, Khoo, Saye, Siccardi, Marco, Liptrott, Neill, Saye H. Khoo, Wai San Kwan, Andrew Owen, Owen, Andrew, Moss, Darren, Neill J. Liptrott   +15 more
core   +2 more sources

Altered subcutaneous adipose tissue parameters after switching ART-controlled HIV+ patients to raltegravir/maraviroc

AIDS (London), 2021
Supplemental Digital Content is available in the text Objective: To evaluate the effect on anthropometric, metabolic and adipose tissue parameters of switching ART-controlled persons living with HIV (PLWH) from a protease inhibitor regimen to raltegravir/
J. Bastard, V. Pelloux, R. Alili, S. Fellahi, J. Aron‐Wisnewsky, Emilie Capel, B. Fève, L. Assoumou, Edi Prifti, C. Katlama, K. Clément, J. Capeau   +11 more
semanticscholar   +1 more source

Three main mutational pathways in HIV-2 lead to high-level raltegravir and elvitegravir resistance: implications for emerging HIV-2 treatment regimens. [PDF]

PLoS ONE, 2012
Human immunodeficiency virus type 2 (HIV-2) is intrinsically resistant to non-nucleoside reverse transcriptase inhibitors and exhibits reduced susceptibility to several of the protease inhibitors used for antiretroviral therapy of HIV-1. Thus, there is a
Robert A Smith, Dana N Raugi, Charlotte Pan, Matthew Coyne, Alexandra Hernandez, Brad Church, Kara Parker, James I Mullins, Papa Salif Sow, Geoffrey S Gottlieb, University of Washington-Dakar HIV-2 Study Group   +10 more
doaj   +1 more source